About: X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.24 (+1.25%)
XFOR NASDAQ X4 Pharmaceuticals Inc
X4 Pharmaceuticals Inc share price
Atividade de preço de XFOR
Último preço
$ 3,240
Variação (24h)
0,04 USD (1,25%)
Volume
535.32K
Volume (média 4 sem.)
-
Abertura
$ 3,16
Variação do dia
$ 3,02 - $ 3,25
Fechamento anterior
$ 3,20
Último negócio
23 Oct, 8:18 pm GMT+0
Atrasado
23 Oct, 8:18 pm GMT+0
XFOR price performance
Atrasado
23 Oct, 8:18 pm GMT+0
quote.marketSignals